{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:45:24Z","timestamp":1793684724619,"version":"4.5.1"},"reference-count":52,"publisher":"Becaris Publishing Limited","issue":"2","funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    The cost\u2013effectiveness of treatment options (anticholinergics, \u03b23-adrenoceptor agonists, onabotulinumtoxinA, sacral nerve stimulation and percutaneous tibial stimulation [the latter two including new rechargeable neurostimulators]) for the management of overactive bladder (OAB) were compared with best supportive care (BSC) using a previously published Markov model.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    Cost\u2013effectiveness was evaluated over a 15-year time horizon, and sensitivity analyses were performed using 2- and 5-year horizons. Discontinuation rates, resource utilization, and costs were derived from published sources.\n                    <jats:bold>Results:<\/jats:bold>\n                    Using Medicare and commercial costs over a 15-year time period, onabotulinumtoxinA 100U had incremental cost\u2013effectiveness ratios (ICERs) gained of $39,591\/quality-adjusted life-year (QALY) and $42,255\/QALY, respectively, versus BSC, which were the lowest ICERs of all assessed treatments. The sensitivity analyses at 2- and 5-year horizons also showed onabotulinumtoxinA to be the most cost-effective of all assessed treatments versus BSC.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    OnabotulinumtoxinA 100U is currently the most cost-effective treatment for OAB.\n                  <\/jats:p>","DOI":"10.2217\/cer-2022-0089","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T07:12:18Z","timestamp":1674112338000},"source":"Crossref","is-referenced-by-count":14,"title":["Cost\u2013effectiveness of overactive bladder treatments from a US commercial and\u00a0payer perspective"],"prefix":"10.57264","volume":"12","author":[{"given":"Brian","family":"Murray","sequence":"first","affiliation":[{"name":"Capital Region Urological Surgeons, 319 S Manning Blvd #106, Albany, NY 12208, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Miles-Thomas","sequence":"additional","affiliation":[{"name":"Eastern Virginia Medical School, 225 Clearfield Ave, Virginia Beach, VA 23462, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J","family":"Park","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor B","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Curta, Inc., 4872 Beach Dr SW, Seattle, WA 98116, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Tung","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie company, 2525 Dupont Drive, Irvine, CA 92612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Gillard","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie company, 2525 Dupont Drive, Irvine, CA 92612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Lalla","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie company, 2525 Dupont Drive, Irvine, CA 92612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor W","family":"Nitti","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at UCLA, 300 Stein Plaza Driveway, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Chermansky","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center Magee Womens Hospital, 300 Halket St, Suite 2541, Pittsburgh, PA 15213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"2","key":"e_1_3_6_3_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams P","year":"2002","unstructured":"Abrams P, Cardozo L, Fall M The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn 21(2), 167\u2013178 (2002).","journal-title":"Neurourol. Urodyn"},{"issue":"1","key":"e_1_3_6_4_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/nau.20798","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"29","author":"Haylen BT","year":"2010","unstructured":"Haylen BT, De Ridder D, Freeman RM An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol. Urodyn. 29(1), 4\u201320 (2010).","journal-title":"Neurourol. Urodyn."},{"issue":"6","key":"e_1_3_6_5_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart WF","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW Prevalence and burden of overactive bladder in the United States. World J. Urol. 20(6), 327\u2013336 (2003).","journal-title":"World J. Urol."},{"issue":"2","key":"e_1_3_6_6_2","first-page":"130","article-title":"Economic burden of urgency urinary incontinence in the United States: a systematic review","volume":"20","author":"Coyne KS","year":"2014","unstructured":"Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J. Manag. Care Pharm. 20(2), 130\u2013140 (2014).","journal-title":"J. Manag. Care Pharm."},{"issue":"6","key":"e_1_3_6_7_2","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.juro.2012.09.079","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline","volume":"188","author":"Gormley EA","year":"2012","unstructured":"Gormley EA, Lightner DJ, Burgio KL Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline. J. Urol. 188(Suppl. 6), 2455\u20132463 (2012).","journal-title":"J. Urol."},{"issue":"3","key":"e_1_3_6_8_2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/JU.0000000000000309","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment 2019","volume":"202","author":"Lightner DJ","year":"2019","unstructured":"Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment 2019. J. Urol. 202(3), 558\u2013563 (2019).","journal-title":"J. Urol."},{"issue":"4","key":"e_1_3_6_9_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/luts.12262","article-title":"Pathophysiology of refractory overactive bladder","volume":"11","author":"Chen LC","year":"2019","unstructured":"Chen LC, Kuo HC. Pathophysiology of refractory overactive bladder. Low. Urin. Tract Symptoms 11(4), 177\u2013181 (2019).","journal-title":"Low. Urin. Tract Symptoms"},{"issue":"7","key":"e_1_3_6_10_2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s11255-016-1277-0","article-title":"Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study","volume":"48","author":"Chancellor MB","year":"2016","unstructured":"Chancellor MB, Yehoshua A, Waweru C Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study. Int. Urol. Nephrol. 48(7), 1029\u20131036 (2016).","journal-title":"Int. Urol. Nephrol."},{"issue":"4","key":"e_1_3_6_11_2","first-page":"406","article-title":"Health resource utilization and cost for patients with incontinent overactive bladder treated with anticholinergics","volume":"22","author":"Yehoshua A","year":"2016","unstructured":"Yehoshua A, Chancellor M, Vasavada S Health resource utilization and cost for patients with incontinent overactive bladder treated with anticholinergics. J. Manag. Care Spec. Pharm. 22(4), 406\u2013413 (2016).","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"11","key":"e_1_3_6_12_2","doi-asserted-by":"crossref","first-page":"e021889","DOI":"10.1136\/bmjopen-2018-021889","article-title":"Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review","volume":"8","author":"Yeowell G","year":"2018","unstructured":"Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open 8(11), e021889 (2018).","journal-title":"BMJ Open"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0079"},{"key":"e_1_3_6_14_2","unstructured":"Urovant Sciences Inc. Gemtesa (vibegron) prescribing information. (2020)."},{"key":"e_1_3_6_15_2","unstructured":"Axonics. Axonics Sacral Neuromodulation System summary of safety and effectiveness data. (2019)."},{"issue":"1","key":"e_1_3_6_16_2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/JU.0000000000000458","article-title":"Treatment of urinary urgency incontinence using a rechargeable SNM system: 6-month results of the ARTISAN-SNM study","volume":"203","author":"Mccrery R","year":"2020","unstructured":"Mccrery R, Lane F, Benson K Treatment of urinary urgency incontinence using a rechargeable SNM system: 6-month results of the ARTISAN-SNM study. J. Urol. 203(1), 185\u2013192 (2020).","journal-title":"J. Urol."},{"issue":"2","key":"e_1_3_6_17_2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s12325-019-01205-z","article-title":"New technologies and applications in sacral neuromodulation: an update","volume":"37","author":"De Wachter S","year":"2020","unstructured":"De Wachter S, Knowles CH, Elterman DS New technologies and applications in sacral neuromodulation: an update. Adv. Ther. 37(2), 637\u2013643 (2020).","journal-title":"Adv. Ther."},{"key":"e_1_3_6_18_2","unstructured":"Medicare Payment Advisory Commission. March 2020 Report to the Congress: Medicare payment policy. (2020). www.medpac.gov\/document\/http-www-medpac-gov-docs-default-source-reports-mar20_entirereport_sec-pdf\/"},{"key":"e_1_3_6_19_2","unstructured":"York Health Economics Consortium. Allergan data on file. Network meta-analysis for BOTOX: mirabegron and anticholinergics. (2016)."},{"issue":"5","key":"e_1_3_6_20_2","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/bju.13945","article-title":"Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis","volume":"120","author":"Drake MJ","year":"2017","unstructured":"Drake MJ, Nitti VW, Ginsberg DA Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis. BJU Int 120(5), 611\u2013622 (2017).","journal-title":"BJU Int"},{"issue":"2","key":"e_1_3_6_21_2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple C","year":"2013","unstructured":"Chapple C, Sievert KD, Macdiarmid S OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur. Urol. 64(2), 249\u2013256 (2013).","journal-title":"Eur. Urol."},{"issue":"6","key":"e_1_3_6_22_2","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase III, randomized, placebo controlled trial","volume":"189","author":"Nitti VW","year":"2013","unstructured":"Nitti VW, Dmochowski R, Herschorn S OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase III, randomized, placebo controlled trial. J. Urol. 189(6), 2186\u20132193 (2013).","journal-title":"J. Urol."},{"issue":"3","key":"e_1_3_6_23_2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.juro.2016.03.146","article-title":"Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5-year study","volume":"196","author":"Nitti VW","year":"2016","unstructured":"Nitti VW, Ginsberg D, Sievert KD Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5-year study. J. Urol. 196(3), 791\u2013800 (2016).","journal-title":"J. Urol."},{"issue":"2","key":"e_1_3_6_24_2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/nau.22707","article-title":"Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder","volume":"35","author":"Noblett K","year":"2016","unstructured":"Noblett K, Siegel S, Mangel J Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Neurourol. Urodyn. 35(2), 246\u2013251 (2016).","journal-title":"Neurourol. Urodyn."},{"issue":"4","key":"e_1_3_6_25_2","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/nau.23076","article-title":"Detailed analysis of adverse events and surgical interventions in a large prospective trial of sacral neuromodulation therapy for overactive bladder patients","volume":"36","author":"Noblett K","year":"2017","unstructured":"Noblett K, Benson K, Kreder K. Detailed analysis of adverse events and surgical interventions in a large prospective trial of sacral neuromodulation therapy for overactive bladder patients. Neurourol. Urodyn. 36(4), 1136\u20131139 (2017).","journal-title":"Neurourol. Urodyn."},{"issue":"2","key":"e_1_3_6_26_2","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1002\/nau.23465","article-title":"Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder","volume":"37","author":"Blok B","year":"2018","unstructured":"Blok B, Van Kerrebroeck P, De Wachter S Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder. Neurourol. Urodyn. 37(S2), S9\u2013S16 (2018).","journal-title":"Neurourol. Urodyn."},{"issue":"2","key":"e_1_3_6_27_2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/nau.23892","article-title":"A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study","volume":"38","author":"Blok B","year":"2019","unstructured":"Blok B, Van Kerrebroeck P, De Wachter S A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study. Neurourol. Urodyn. 38(2), 689\u2013695 (2019).","journal-title":"Neurourol. Urodyn."},{"issue":"3","key":"e_1_3_6_28_2","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.juro.2010.10.060","article-title":"National trends in the usage and success of sacral nerve test stimulation","volume":"185","author":"Cameron AP","year":"2011","unstructured":"Cameron AP, Anger JT, Madison R, Saigal CS, Clemens JQ, Urologic Diseases in America Project. National trends in the usage and success of sacral nerve test stimulation. J. Urol. 185(3), 970\u2013975 (2011).","journal-title":"J. Urol."},{"issue":"1","key":"e_1_3_6_29_2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/nau.22266","article-title":"Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study","volume":"32","author":"Peters KM","year":"2013","unstructured":"Peters KM, Carrico DJ, Macdiarmid SA Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study. Neurourol. Urodyn. 32(1), 24\u201329 (2013).","journal-title":"Neurourol. Urodyn."},{"issue":"6","key":"e_1_3_6_30_2","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.juro.2012.11.175","article-title":"Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study","volume":"189","author":"Peters KM","year":"2013","unstructured":"Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, Macdiarmid SA. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. J. Urol. 189(6), 2194\u20132201 (2013).","journal-title":"J. Urol."},{"issue":"4","key":"e_1_3_6_31_2","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.juro.2009.12.036","article-title":"Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial","volume":"183","author":"Peters KM","year":"2010","unstructured":"Peters KM, Carrico DJ, Perez-Marrero RA Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J. Urol. 183(4), 1438\u20131443 (2010).","journal-title":"J. Urol."},{"key":"e_1_3_6_32_2","unstructured":"Micron Medical. Micron Medical Corporate Presentation. (2020)."},{"issue":"6","key":"e_1_3_6_33_2","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/bju.12972","article-title":"The cost\u2013effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK [retracted article]","volume":"116","author":"Autiero SW","year":"2015","unstructured":"Autiero SW, Hallas N, Betts CD, Ockrim JL. The cost\u2013effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK [retracted article]. BJU Int. 116(6), 945\u2013954 (2015).","journal-title":"BJU Int."},{"key":"e_1_3_6_34_2","unstructured":"National Institute for Health and Clinical Excellence. Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome: Interventional procedures guidance [IPG362]. (2010). https:\/\/www.nice.org.uk\/guidance\/IPG362 (September 19 2022)."},{"issue":"2","key":"e_1_3_6_35_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jval.2012.12.005","article-title":"Mapping EQ-5D utility scores from the Incontinence Quality of Life Questionnaire among patients with neurogenic and idiopathic overactive bladder","volume":"16","author":"Kay S","year":"2013","unstructured":"Kay S, Tolley K, Colayco D, Khalaf K, Anderson P, Globe D. Mapping EQ-5D utility scores from the Incontinence Quality of Life Questionnaire among patients with neurogenic and idiopathic overactive bladder. Value Health 16(2), 394\u2013402 (2013).","journal-title":"Value Health"},{"key":"e_1_3_6_36_2","unstructured":"Ibm Micromedex. RED BOOK Online. A comprehensive consistent drug pricing resource. www.ibm.com\/products\/micromedex-red-book"},{"key":"e_1_3_6_37_2","unstructured":"American Medical Association. Code Book. (2016). https:\/\/ocm.ama-assn.org\/OCM\/CPTRelativeValueSearch.do"},{"key":"e_1_3_6_38_2","unstructured":"Allergan Plc. MarketScan. Data on file. (2016)."},{"issue":"2","key":"e_1_3_6_39_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ajog.2013.07.025","article-title":"Sacral nerve stimulation for the treatment of refractory voiding and bowel dysfunction","volume":"210","author":"Noblett KL","year":"2014","unstructured":"Noblett KL, Cadish LA. Sacral nerve stimulation for the treatment of refractory voiding and bowel dysfunction. Am. J. Obstet. Gynecol. 210(2), 99\u2013106 (2014).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"e_1_3_6_40_2","unstructured":"Noridian Healthcare Solutions Durable Medical Equipment Coding System Fee Schedule Lookup Tool. https:\/\/med.noridianmedicare.com\/web\/jddme\/fees-news\/fee-schedules\/lookup-tool"},{"key":"e_1_3_6_41_2","unstructured":"Centers for Medicare and Medicaid Services. Medicare Physician fee schedule. www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/PhysicianFeeSched\/"},{"key":"e_1_3_6_42_2","unstructured":"Centers for Medicare and Medicaid Services. Ambulatory Surgical Center (ASC) payment rates. www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/ASCPayment\/archive.html"},{"key":"e_1_3_6_43_2","unstructured":"Blue Cross Blue Shield. Medical coverage policies: sacral nerve stimulation. (2008). www.bcbsri.com\/sites\/default\/files\/polices\/SacralNerveStimulation.pdf"},{"key":"e_1_3_6_44_2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1477-7525-1-80","article-title":"Problems and solutions in calculating quality-adjusted life years (QALYs)","volume":"1","author":"Prieto L","year":"2003","unstructured":"Prieto L, Sacrist\u00e1n JA. Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual. Life Outcomes 1, 80 (2003).","journal-title":"Health Qual. Life Outcomes"},{"issue":"1","key":"e_1_3_6_45_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/M20-1392","article-title":"A health opportunity cost threshold for cost\u2013effectiveness analysis in the United States","volume":"174","author":"Vanness DJ","year":"2021","unstructured":"Vanness DJ, Lomas J, Ahn H. A health opportunity cost threshold for cost\u2013effectiveness analysis in the United States. Ann. Intern. Med. 174(1), 25\u201332 (2021).","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"e_1_3_6_46_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00192-020-04423-0","article-title":"OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real-world practice","volume":"32","author":"Hamid R","year":"2021","unstructured":"Hamid R, Lorenzo-Gomez MF, Schulte-Baukloh H, Boroujerdi A, Patel A, Farrelly E. OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real-world practice. Int. Urogynecol. J. 32(1), 65\u201374 (2021).","journal-title":"Int. Urogynecol. J."},{"issue":"7","key":"e_1_3_6_47_2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/SPV.0000000000000914","article-title":"Early and consistent improvements in urinary symptoms and quality of life with onabotulinumtoxinA in patients with overactive bladder and urinary incontinence: results from a randomized, placebo-controlled, phase IV clinical trial","volume":"27","author":"Mccammon K","year":"2021","unstructured":"Mccammon K, Gousse A, Kohan A Early and consistent improvements in urinary symptoms and quality of life with onabotulinumtoxinA in patients with overactive bladder and urinary incontinence: results from a randomized, placebo-controlled, phase IV clinical trial. Female Pelvic Med. Reconstr. Surg. 27(7), 450\u2013456 (2021).","journal-title":"Female Pelvic Med. Reconstr. Surg."},{"issue":"5","key":"e_1_3_6_48_2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/SPV.0b013e31822f816f","article-title":"Repeat intradetrusor injections of onabotulinum toxin A for refractory idiopathic overactive bladder patients: a single-center experience","volume":"17","author":"Gousse AE","year":"2011","unstructured":"Gousse AE, Kanagarajah P, Ayyathurai R, Handa P, Dabas N, Gomez CS. Repeat intradetrusor injections of onabotulinum toxin A for refractory idiopathic overactive bladder patients: a single-center experience. Female Pelvic Med. Reconstr. Surg. 17(5), 253\u2013257 (2011).","journal-title":"Female Pelvic Med. Reconstr. Surg."},{"issue":"5","key":"e_1_3_6_49_2","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/JU.0000000000000656","article-title":"Cost\u2013effectiveness of sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: results of the ROSETTA randomized trial","volume":"203","author":"Harvie HS","year":"2020","unstructured":"Harvie HS, Amundsen CL, Neuwahl SJ Cost\u2013effectiveness of sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: results of the ROSETTA randomized trial. J. Urol. 203(5), 969\u2013977 (2020).","journal-title":"J. Urol."},{"issue":"4","key":"e_1_3_6_50_2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1464-410X.2010.09905.x","article-title":"Cost\u2013effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder","volume":"108","author":"Leong RK","year":"2011","unstructured":"Leong RK, De Wachter SG, Joore MA, Van Kerrebroeck PEV. Cost\u2013effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. BJU Int. 108(4), 558\u2013564 (2011).","journal-title":"BJU Int."},{"issue":"2","key":"e_1_3_6_51_2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jval.2010.08.006","article-title":"Cost\u2013effectiveness of sacral neuromodulation compared to botulinum neurotoxin A or continued medical management in refractory overactive bladder","volume":"14","author":"Arlandis S","year":"2011","unstructured":"Arlandis S, Castro D, Errando C Cost\u2013effectiveness of sacral neuromodulation compared to botulinum neurotoxin A or continued medical management in refractory overactive bladder. Value Health 14(2), 219\u2013228 (2011).","journal-title":"Value Health"},{"issue":"8","key":"e_1_3_6_52_2","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00345-014-1401-7","article-title":"Sacral neuromodulation and botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System","volume":"33","author":"Bertapelle MP","year":"2015","unstructured":"Bertapelle MP, Vottero M, Popolo GD Sacral neuromodulation and botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System. World J. Urol. 33(8), 1109\u20131117 (2015).","journal-title":"World J. Urol."},{"issue":"7","key":"e_1_3_6_53_2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5489\/cuaj.2711","article-title":"Economic evaluation of sacral neuromodulation in overactive bladder: a Canadian perspective","volume":"9","author":"Hassouna MM","year":"2015","unstructured":"Hassouna MM, Sadri H. Economic evaluation of sacral neuromodulation in overactive bladder: a Canadian perspective. Can. Urol. Assoc. J. 9(7\u20138), 242\u2013247 (2015).","journal-title":"Can. Urol. Assoc. J."},{"issue":"2","key":"e_1_3_6_54_2","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.1111\/bju.14204","article-title":"Retraction: The cost\u2013effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK","volume":"122","year":"2018","unstructured":"Retraction: The cost\u2013effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK. BJU Int. 122(2), E3 (2018).","journal-title":"BJU Int."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.futuremedicine.com\/doi\/pdf\/10.2217\/cer-2022-0089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T09:57:47Z","timestamp":1676627867000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2022-0089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.2217\/cer-2022-0089"],"URL":"https:\/\/doi.org\/10.2217\/cer-2022-0089","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]},"article-number":"e220089"}}